profit from every ₹100 of sales.
₹0₹100
Laurus Labs
₹2,429.00-1.02% today
+142.6% in 1 year
1-year low ₹930.201-year high ₹2,454.00
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹147.66 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Laurus Labs sold, what it kept, and what it did with the cash.
Sales went from ₹60.1 billion in 2023 to ₹67.2 billion in 2026, with ₹8.89 billion of profit last year.
SalesProfit
Laurus Labs handed back 16% of the cash it generated last year.
₹863M
Free cash flow 2026₹5.5B
Bought back its own shares–
Paid as dividends₹863M
Cash vs. debt₹1.1B vs. ₹25.2B
Laurus Labs vs. similar companies
Laurus Labs grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Laurus Labs | 147.7× · Very expensive | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Laurus Labs's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 60,142 | 50,018 | 55,079 | 67,212 | |
| 31,735 | 25,027 | 29,685 | 39,576 | |
| 12,943 | 3,949 | 6,252 | 13,064 | |
| 15,559 | 7,927 | 11,210 | 18,230 | |
| 7,901 | 1,606 | 3,583 | 8,888 | |
| 14.64 | 2.97 | 6.64 | 16.45 | |
| 52.8% | 50.0% | 53.9% | 58.9% | |
| 21.5% | 7.9% | 11.4% | 19.4% | |
| 13.1% | 3.2% | 6.5% | 13.2% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 76,604 | 83,870 | 93,356 | 105,112 |
| Cash | 457 | 1,389 | 995 | 1,127 |
| Total debt | 20,151 | 25,774 | 27,637 | 25,185 |
| Total liabilities | 36,117 | 42,715 | 47,331 | 50,798 |
| 40,375 | 41,110 | 44,726 | 53,001 | |
| 540 | 540 | 540 | 540 | |
| 15.3% | 4.6% | 7.2% | 12.9% | |
| 19.6% | 3.9% | 8.0% | 16.8% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 9,939 | 6,657 | 6,017 | 16,235 | |
| 9,902 | 6,783 | 6,410 | 10,700 | |
| 37 | -126 | -394 | 5,536 | |
| Dividends paid | 1,075 | 862 | 431 | 863 |
| – | – | – | – | |
| 75 | 109 | 102 | 109 |
Valuation
- 147.7×
- –
- 37.27
- 14.2×
- 19.5×
- 237.1×
- 73.3×
- 0.4%
- 0.7%
- 0.1%
Profitability
- 58.9%
- 19.4%
- 13.2%
- –
- 12.9%
- 10.0%
- –
- –
- –
- –
Growth
- +3.8%
- +4.0%
- –
- –
- +0.1%
Financial health
- 1.3×
- 0.48
- –
- 8.3×
- 1.33
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 18%of 958
Top 25%of 889
Bottom 5%of 601
Bottom 26%of 890
Bottom 42%of 987
0.1%of the share price, paid each year
On $1,000 invested$1a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
9.7% of its profit
Room to growStretchedMore than it earns: 15.6%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
33No pass
Philip Fisher
40No pass
Peter Lynch
22No pass
Joel Greenblatt
8No pass
Charlie Munger
38No pass
Terry Smith
26No pass
Questions about Laurus Labs
Is Laurus Labs a good stock to buy?
A solid business, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Laurus Labs AI analysis
What does Laurus Labs do?
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Hyderabad, India.
Does Laurus Labs pay a dividend?
Yes. At today's price the dividend is 0.1% a year, about 10% of its yearly profit. In 2026 it paid out ₹863 million in dividends.
Is Laurus Labs stock halal?
Yes. Laurus Labs passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Laurus Labs stock done over the past year?
Up 142.6% over the past twelve months, to ₹2,429.00. It traded between ₹930.20 and ₹2,454.00, close to its high.
Who are Laurus Labs's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Laurus Labs's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.